NANO-X IMAGING LTD filings document foreign private issuer disclosures for a medical imaging technology company with ordinary shares listed under NNOX. Recent Form 6-K reports cover financial results, GAAP and non-GAAP measures, business updates, FDA 510(k) clearance for TAP2D on Nanox.ARC and Nanox.ARC X systems, and commercial developments involving Nanox.ARC deployment.
The filing record also includes capital-structure and governance disclosures, including a registered direct offering of ordinary shares, material agreements, incorporation of exhibits into Form F-3 and Form S-8 registration statements, and annual general meeting proxy materials. These documents describe shareholder voting matters, financing activity, operating results, regulatory updates and corporate reporting controls for the company.
Nano-X Imaging Ltd has priced a registered direct offering to a single institutional investor comprising 3,700,000 ordinary shares, 4,300,000 pre-funded warrants and 8,000,000 ordinary warrants, for $8,000,000 in gross proceeds. Each share unit is priced at $1.00 and each pre-funded unit at $0.9999.
The company expects net proceeds of $7.6 million, excluding any warrant exercises, to be used for working capital and general corporate purposes. Ordinary shares outstanding will rise from 70,588,638 to 78,588,638 assuming full exercise of pre-funded warrants and no exercise of ordinary warrants, representing meaningful dilution.
Management discloses substantial doubt about the company’s ability to continue as a going concern, with an accumulated deficit of $463 million as of March 31, 2026 and dependence on additional financing. An impairment assessment of assets and goodwill is underway and may materially affect final financial results.
Nano-X Imaging Ltd. entered into a securities purchase agreement with a single long-term institutional investor for a registered direct offering of 8,000,000 ordinary shares (or equivalents) and warrants to purchase up to 8,000,000 shares at a combined purchase price of $1.00 per share and accompanying warrant. The warrants have an exercise price of $1.15 per share, become exercisable six months after issuance and expire five years after closing, which is expected on or about August 7, 2026, generating expected gross proceeds of approximately $8 million before fees.
The company plans to use net proceeds for working capital and general corporate purposes. It also reports that, while preparing results for the quarter ended June 30, 2026, it has begun a comprehensive impairment assessment of long-lived assets and goodwill with an external appraiser, and notes that final financial results for the period may differ, potentially materially, from preliminary estimates.
Nano-X Imaging Ltd. has a notice indicating a proposed sale of its ordinary shares on Nasdaq through Oppenheimer & Co. Inc.. The holder plans to sell up to 20,000 ordinary shares, which were issued on 11/22/2024 upon the vesting of RSUs for no cash consideration.
Nano-X Imaging Ltd. filed an initial Form 3 for Chief Financial Officer Guy Nathansohn, providing his first reported status as an officer subject to insider disclosure rules.
The filing reports no transactions or derivative positions and refers to Exhibit 24.1, a Power of Attorney authorizing certain SEC filings.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership in NANO-X IMAGING LTD common stock. BlackRock reported beneficial ownership of 255,435 shares, representing 0.4% of the outstanding common stock as of June 30, 2026.
BlackRock reported sole voting and sole dispositive power over all 255,435 shares, with no shared voting or dispositive power. Various underlying clients or investors may have economic interests in these shares, but no single person is reported to hold more than five percent of the company’s outstanding common shares.
Nano-X Imaging Ltd. director Suesskind Dan S reported open-market purchases of a total of 50,000 Ordinary Shares on July 27, 2026, in two blocks of 25,000 shares at $0.94 and $0.92 per share. The Rule 10b5-1 checkbox was not marked for these transactions.
He also reports outstanding stock options to acquire 12,505 shares at $64.6100, 50,000 shares at $17.6300, and 10,000 shares at $11.5200, with expirations between 2031 and 2033, plus time-vested RSUs granted in 2024 and 2025.
Nano-X Imaging Ltd. director Kainan Noga purchased 33,000 ordinary shares on July 28, 2026 at $0.9000 per share in an open-market or private transaction. He also reports existing stock options over 12,505, 50,000 and 10,000 shares at exercise prices of $64.6100, $17.6300 and $11.5200, plus 794 ordinary shares held indirectly through I.B.L. Business Consulting Ltd. Additional ordinary shares are reported as underlying restricted share units granted December 10, 2025 that vest in twelve equal monthly installments.
Nano-X Imaging Ltd. CFO Daniel Ran reported a disposition of 1,000 Ordinary Shares back to the issuer on 2026-07-29 at $0.89 per share. After this issuer-related transaction, Ran directly holds 5,950 Ordinary Shares. The transaction is classified as a disposition to the issuer and was not marked as made under a Rule 10b5-1 trading plan.
A shareholder of Nano-X Imaging Ltd. (NNOX) has filed a notice of proposed sale of ordinary shares. The filing lists ordinary shares to be sold through Etrade and Altshare, with indicated quantities of 1,000 and 5,950 shares and aggregate market values of 880.00 and 5,236.00, respectively, to be sold on Nasdaq in late July 2026.
The shareholder reports that the 1,000 shares were acquired by purchase on 09/05/2025 through Etrade as a purchase in the open market, and that 5,950 shares were acquired via an RSU Grant on 04/16/2024. These details document how the securities were obtained prior to the planned sales.
Nano-X Imaging Chief Executive Officer Erez Meltzer, through his wholly owned company Oud Nof, purchased 36,000 ordinary shares on July 27, 2026 at $0.93 per share, reported as indirect ownership. The report also lists existing direct holdings of 60,584 shares and several vested and vesting stock option grants with exercise prices between $2.21 and $23.84, expiring from 2030 to 2034.